Sonoma Pharmaceuticals (SNOA) Cost of Revenue (2010 - 2025)

Sonoma Pharmaceuticals' Cost of Revenue history runs 16 years deep, the most recent figure standing at $2.7 million for Q4 2025.

• In Q4 2025, Cost of Revenue rose 17.65% year-over-year to $2.7 million; the TTM figure through Dec 2025 stood at $11.0 million (up 22.53% YoY), while the FY2025 annual figure was $8.8 million, up 10.43% from the prior year.
• Cost of Revenue was $2.7 million for Q4 2025 at Sonoma Pharmaceuticals, down from $3.5 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $3.5 million in Q3 2025 to a low of $1.7 million in Q4 2023.
• Historically, Cost of Revenue has averaged $2.2 million across 5 years, with a median of $2.2 million in 2023.
• The sharpest annual moves came in 2021 and 2025: Cost of Revenue tumbled 42.23% in 2021, then soared 57.08% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $1.7 million in 2021, then grew by 24.37% to $2.1 million in 2022, then retreated by 20.59% to $1.7 million in 2023, then soared by 36.71% to $2.3 million in 2024, then climbed by 17.65% to $2.7 million in 2025.
• The last three Cost of Revenue figures came in at $2.7 million (Q4 2025), $3.5 million (Q3 2025), and $2.6 million (Q2 2025), per Business Quant data.